Achievement of clinical, endoscopic, and histologic outcomes in patients with ulcerative colitis treated with etrasimod, and association with fecal calprotectin and C-reactive protein: results from the Phase 2 OASIS trial.
Andres J YarurMichael V ChioreanJulián PanésVipul JairathJinkun ZhangChristopher J RabbatWilliam J SandbornSéverine VermeireLaurent Peyrin-BirouletPublished in: Journal of Crohn's & colitis (2024)
Etrasimod was effective for inducing EIHR in patients with UC. FCP and CRP may be useful, noninvasive biomarkers to monitor treatment response.